Overview:
The FDA has been moving in the direction of newer technology in an effort to no longer be a bottleneck to industry innovation.
As part of the Case for Quality program US FDA Center for Devices and Radiological Health noted how an excessive focus by industry on compliance rather than quality may be diverting resources and management attention toward meeting regulatory compliance requirements vs. investing in automation and digital technologies, which could greatly improve quality and process control.
A key element is a risk-based, product quality and patient-centric approach to Computer System Assurance (CSA), issued as a draft guidance in September 2022 vs. the traditional Computer System Validation (CSV) waterfall approach. CSA encourages critical thinking based on product and process knowledge and quality risk management over prescriptive documentation driven approaches. It also provides the ability to use automated testing to improve validation efficiency and effectiveness.
This is where FDA determined that "WHAT" is required can be done in different ways (the "HOW") and does not have to be according to the "checklist" mindset of most CSV work, where you crank out documents without specifically addressing the risk of potential failure of each requirement.
GAMP®5 supports the use of incremental, iterative, and evolutionary approaches including agile and automated testing for development of custom applications. Keys to success include a robust Quality Management System (QMS) and well trained and highly disciplined teams following well-defined processes supported by tools and automation.
Why you should Attend:
The attendee will learn about FDA's approach to modernizing technology, and how that will benefit both the Agency and industry. We will discuss ways to modernize the System Development Life Cycle (SDLC) approach to software development, testing, and release, Computer System Validation (CSV), and Computer Software Assurance (CSA) by using automated testing tools that will result in a continuous validation of software products. This approach is amenable to the agile software development methodology, which can be adapted for use in validation. We'll discuss the pros and cons of each approach, and industry best practices for success.
You'll learn how the newest version of GAMP®5 2nd Edition issued in July 2022 aligns with the CSA approach, addressing non-linear forms of software development, testing, and release, such as agile. This provides a more efficient and effective way to ensure software changes can be done much more quickly using automated testing.
We'll cover Computer-Off-the-Shelf (COTS) software, Software-as-a-Service (SaaS), Infrastructure-as-a-Service (IaaS), Platform-as-a-Service (PaaS), and cloud services. You'll learn how to select an optimal solution and ensure that whatever that might be, you can build a contract and Service Level Agreement (SLA) that best suits your environment and needs.
We'll also provide new approaches for meeting 21 CFR Part 11, FDA's guidance for electronic records & electronic signatures, and also data integrity requirements, based on the "ALCOA+" principles: Attributable, Legible, Contemporaneous, Original or "True" Copy, Accurate, Complete, Consistent, Enduring, & Available.
Areas Covered in the Session:
Who Will Benefit:
Carolyn (McKillop) Troiano has more than 35 years of experience in the tobacco, pharmaceutical, medical device and other FDA-regulated industries. She has worked directly, or on a consulting basis, for many of the larger pharmaceutical and tobacco companies in the US and Europe, developing and executing compliance strategies and programs.
Carolyn is currently active in the Association of Information Technology Professionals (AITP), and Project Management Institute (PMI) chapters in the Richmond, VA area.
During her career, Carolyn worked directly, or on a consulting basis, for many of the larger pharmaceutical companies in the US and Europe. She developed validation programs and strategies back in the mid-1980s, when the first FDA guidebook was published on the subject, and collaborated with FDA and other industry representatives on 21 CFR Part 11, the FDA's electronic record/electronic signature regulation.